Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler®

M. Everard, S. Ellis, S. Das (Sheffield, St Albans, United Kingdom)

Source: Annual Congress 2003 - New aspects of asthma treatment
Session: New aspects of asthma treatment
Session type: Thematic Poster Session
Number: 1982
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Everard, S. Ellis, S. Das (Sheffield, St Albans, United Kingdom). Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler®. Eur Respir J 2003; 22: Suppl. 45, 1982

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide?
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020


Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019
Year: 2020



Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 429s
Year: 2002

Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg
Source: International Congress 2017 – Inhalers and their use
Year: 2017

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400μg) administered by turbuhaler with beclomethasone dipropionate (400μg) given twice daily through a metered-dose inhaler in patients with mild to
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 337s
Year: 2001

Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 350s
Year: 2007

Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R)
Source: Eur Respir J 2001; 17: 1332-1333
Year: 2001


A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Addition of formoterol Turbuhaler® to budesonide Turbuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial
Source: Eur Respir J 2001; 18: Suppl. 33, 330s
Year: 2001

Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003

Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011